Serkan Akın
Impact in
-
- Inflammatory Biomarkers in Disease Prognosis
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 14
- Inflammatory Biomarkers in Disease Prognosis 3
- HER2/EGFR in Cancer Research 3
- Cancer Risks and Factors 2
- Cancer Immunotherapy and Biomarkers 2
-
- Lymphoma Diagnosis and Treatment 7
- Co-authors
- Kadri Altundağ (15 shared papers)Taha Koray Şahin (7 shared papers)Deniz Can Guven (10 shared papers)Taner Babacan (12 shared papers)Furkan Sarici (9 shared papers)Samer Ali Srour (1 shared paper)Sercan Aksoy (11 shared papers)Öztürk Ateş (10 shared papers)
- Journals
- The Oncologist (2 papers)Cancer Control (2 papers)Journal of Clinical Medicine (2 papers)Annals of Hematology (2 papers)Future Oncology (2 papers)
- Partner nations
- TürkiyeUnited States
In The Last Decade
Serkan Akın
48 papers receiving 286 citations
Peers
Comparison fields: 5 of 44
- Oncology 105
- Cancer Research 43
- Pathology and Forensic Medicine 29
- Health 11
- Genetics 10
Countries citing papers authored by Serkan Akın
This map shows the geographic impact of Serkan Akın's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serkan Akın with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serkan Akın more than expected).
Fields of papers citing papers by Serkan Akın
This network shows the impact of papers produced by Serkan Akın. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serkan Akın. The network helps show where Serkan Akın may publish in the future.
Co-authors
The 25 scholars most cited alongside Serkan Akın, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 23 | |
| 2 | A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors. | 2014 | 18 |
| 3 | 2017 | 18 | |
| 4 | 2022 | 17 | |
| 5 | 2022 | 17 | |
| 6 | Molecular subtypes in patients with inflammatory breast cancer; a single center experience. | 2015 | 16 |
| 7 | Association between androgen receptor status and prognosis in triple negative breast cancer. | 2019 | 15 |
| 8 | 2018 | 12 | |
| 9 | 2024 | 12 | |
| 10 | 2015 | 9 | |
| 11 | 2022 | 9 | |
| 12 | 2024 | 9 | |
| 13 | 2017 | 8 | |
| 14 | 2018 | 8 | |
| 15 | 2021 | 8 | |
| 16 | Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats. | 2015 | 7 |
| 17 | Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. | 2016 | 7 |
| 18 | Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study. | 2020 | 7 |
| 19 | 2009 | 6 | |
| 20 | 2016 | 6 |
About Serkan Akın
Serkan Akın is a scholar working on Oncology, Pathology and Forensic Medicine, Cancer Research, Hematology and Genetics, having authored 53 papers that have together received 296 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Breast Cancer Treatment Studies (6 papers), Multiple Myeloma Research and Treatments (3 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Risks and Factors (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Oncology (105 citations), Cancer Research (43 citations), Pathology and Forensic Medicine (29 citations), Health (11 citations) and Genetics (10 citations). Serkan Akın has collaborated with scholars based in Türkiye and United States. Frequent co-authors include Kadri Altundağ, Taha Koray Şahin, Deniz Can Guven, Taner Babacan, Furkan Sarici, Samer Ali Srour, Sercan Aksoy, Öztürk Ateş, Ömer Dızdar and Fatih Mehmet Uckun. Their work appears in journals such as The Oncologist, Cancer Control, Journal of Clinical Medicine, Annals of Hematology and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.